Search clinical trials for: Octreotide LAR

Total 2562 results

Peking University

Completed

IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC

Progression Free Survival of the Treatment

China
Memorial Sloan Kettering Cancer Center

Completed

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Neuroendocrine Tumors

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients (HOSCAR)

Acromegaly

Italy, France, Portugal, Poland, Switzerland
Radboud University Medical Center
University Medical Center Groningen; Catharina Ziekenhuis Eindhoven; St. Antonius... and other collaborators

Completed

Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias (OCEAN)

Anemia | Vascular Malformations | Gastrointestinal Hemorrhage | Angiodysplasia

Netherlands
Endo Pharmaceuticals

Terminated

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Acromegaly

United States, Czech Republic, Germany, Hungary, Poland, Russian Federation, Serbia, Slovakia, Spain
University of Turin, Italy

Unknown

Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors (XELBEVOCT)

Neuroendocrine Carcinomas

Italy
National Institute of Diabetes and Digestive and...

Completed

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

Acromegaly | Pituitary Neoplasm

United States
St. Josef Hospital Bochum

Completed

Effects of Intraarterial Octreotide on Pancreatic Texture

Pancreatic Fistula

Germany
Novartis Pharmaceuticals

Completed

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Peritoneal Neoplasms | Intestinal Obstruction | Carcinomatosis

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (PAOLA)

Acromegaly

United States, Italy, Belgium, Saudi Arabia, Spain, France, Germany, Canada, United Kingdom, Colombia, Brazil, Israel, Turkey, Romania, Norway, Poland, Russian Federation, Argentina
US Department of Veterans Affairs

Completed

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

Cirrhosis | Ascites

United States
Novartis Pharmaceuticals

Completed

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Acromegaly

Germany
AdventHealth

Terminated

Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

Adenoma

United States
University of Alberta
Novartis

Completed

The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction

Refractory Ascites | Type 2 Hepatorenal Syndrome

Canada
Aspireo Pharmaceuticals Limited

Completed

Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173

Healthy
Novartis Pharmaceuticals

Completed

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Neoplasms

Spain, Netherlands, Italy, Korea, Republic of, Thailand, Turkey, United States, Russian Federation, Czechia
Mayo Clinic

Completed

Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis

Cirrhosis | Portal Hypertension | Esophageal Varices
Chengfeng Wang

Unknown

The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial

Pancreatic Diseases

China
Qilu Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers

Healthy Volunteers

China
Qilu Hospital of Shandong University

Not yet recruiting

A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

China
Novartis Pharmaceuticals

Completed

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor (RADIANT-2)

Carcinoid Tumor | Malignant Carcinoid Syndrome

France, Spain, Netherlands, United States, Canada, Sweden, Italy, Australia, Germany, Greece, Belgium, Czech Republic, Slovakia, Finland, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Symptomatic Refractory Resistant Carcinoid Disease

United Kingdom, Belgium, Italy, Singapore, Austria, France, Israel, Sweden, Germany, Spain, Canada, Argentina, Poland, United States, Brazil, Norway
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Head and Neck Cancer | Metastatic Cancer | Pheochromocytoma | Islet Cell Tumor

United States
Endo Pharmaceuticals

Completed

Open Label Study of Octreotide Implant in Patients With Acromegaly

Acromegaly
Institut National de la Santé Et de la Recherche...

Completed

Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide (FIBROSAND)

Idiopathic Pulmonary Fibrosis
National Center for Research Resources (NCRR)
Yale University

Completed

Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia

Hereditary Hemorrhagic Telangiectasia | Ectasia
Grupo Espanol de Tumores Neuroendocrinos
Pfizer

Active, not recruiting

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Neuroendocrine Tumors | Advanced Cancer

Spain, Germany, Italy, United Kingdom
Aspireo Pharmaceuticals Limited

Completed

Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.

Acromegaly
Duke University

Completed

Effect of Octreotide on Saliva

Healthy

United States
University Hospital, Rouen

Completed

Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone (SAPORO)

Acromegaly

France
Novartis

Completed

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Diabetic Retinopathy

United States
Fredrik Klevebro
Karolinska University Hospital

Recruiting

Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients With Esophageal or Gastric Cancer (OTIS)

Gastric Cancer | Esophageal Cancer

Sweden
Novartis Pharmaceuticals

Completed

Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers

Healthy Cholecystectomized

France, Italy, Belgium
Nanjing Legend Biotech Co.
Janssen Research & Development, LLC

Recruiting

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1)

Multiple Myeloma

China
Beijing Boren Hospital
Nanjing Legend Biotech Co.

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

T-cell Leukemia | T Cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west...

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

China
Aspireo Pharmaceuticals Limited

Completed

The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics

Acromegaly
Novartis Pharmaceuticals

Terminated

Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas

Acromegaly

Mexico
National Hepatology & Tropical Medicine Research...

Recruiting

Role of Octreotide in Non Variceal Bleeding

Non-variceal Gastrointestinal Bleeding

Egypt
Beijing Children's Hospital

Completed

Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia (BCH)

Congenital Hyperinsulinaemic Hypoglycaemia | Octreotide Adverse Reaction

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Octreotide in Treating Patients With Cancer-Related Malignant Ascites

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer

United States
Chiasma, Inc.

Unknown

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly (OPTIMAL)

Acromegaly

United States, Israel, Canada, Denmark, Netherlands, New Zealand, Australia, United Kingdom, Hungary, Italy, Poland, Bulgaria, Germany, Latvia, Slovenia, Sweden, Turkey
Northwestern University
National Cancer Institute (NCI)

Completed

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Small Intestine Cancer | Ovarian Cancer | Peritoneal Cavity Cancer | Gastrointestinal Stromal Tumor | Extrahepatic Bile Duct Cancer | Nausea and Vomiting | Constipation, Impaction, and Bowel Obstruction

United States
Radiomedix, Inc.
Orano Med LLC

Active, not recruiting

Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (ALPHAMEDIX02)

Neuroendocrine Tumors

United States
University College, London
National Institute for Health Research, United Kingdom

Active, not recruiting

A Feasibility Study of Octreotide Infusion During Liver Transplant. (Octreotide)

Liver Transplantation | Renal Failure

United Kingdom
Rigshospitalet, Denmark
University of Aarhus; Bispebjerg Hospital

Completed

Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial

Lymphatic Diseases | Chylothorax

Denmark
Centre Hospitalier Universitaire, Amiens

Withdrawn

Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock (HemodyNoOc)

Variceal Hemorrhage | Haemorrhagic Shock

France
Lexicon Pharmaceuticals

Completed

Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

Drug Interactions

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Colorectal Cancer | Anal Cancer | Drug/Agent Toxicity by Tissue/Organ | Radiation Enteritis

United States

Search clinical trials for: Octreotide LAR

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations